L-Threonine Encyclopedia — Scientific Background

What Is L-Threonine?

L-Threonine (CAS 72-19-5), also known as (2S,3R)-2-amino-3-hydroxybutanoic acid, is an essential proteinogenic amino acid with the molecular formula C₄H₉NO₃ and a molecular weight of 119.12 g/mol. It occurs as a white crystalline powder or crystalline substance and is freely soluble in water (90 g/L at 20°C), soluble in formic acid, and practically insoluble in ethanol. L-Threonine contains a hydroxyl group in its side chain, classifying it as a polar, uncharged amino acid. It was the last of the essential amino acids to be discovered, identified in 1935 by William Cumming Rose during his studies on the nutritional requirements of rats.

Physiological Functions of L-Threonine

L-Threonine is an essential amino acid with several critical physiological roles:

• Mucin Synthesis — L-Threonine is the most abundant amino acid in gastrointestinal mucin, the gel-like protective layer that lines the intestinal epithelium. The body‘s capacity to maintain adequate mucin synthesis is directly related to the bioavailability of certain amino acids, including threonine, serine and proline.

• Immunoglobulin Production — Threonine is involved in the synthesis of immunoglobulins, which play a critical role in Immune Regulation and host defense.

• Intestinal Immune Modulation — Threonine acts as a nutritional modulator that influences the intestinal immune system via complex signaling networks, particularly mitogen-activated protein kinase (MAPK) and the target of the rapamycin (TOR) signal pathway.

• Protein Synthesis — As a proteinogenic amino acid, L-threonine is a fundamental building block for protein synthesis.

• Metabolic Support — L-Threonine is a precursor for the synthesis of glycine and serine, which are important for collagen synthesis and detoxification pathways.

Mechanisms of Action

Intestinal Barrier Function — Mucin Synthesis

The intestinal mucosal barrier is the body’s first line of defense against luminal bacteria and toxins. The mucin layer that covers the intestinal epithelium is a gel-like secretion composed primarily of highly glycosylated proteins called mucins. L-Threonine is the most abundant amino acid in gastrointestinal mucin, and its availability directly determines the rate of mucin synthesis. Intestinal inflammation is known to increase gastrointestinal threonine uptake and mucin synthesis, indicating that the demand for threonine increases under conditions of gut stress. In animals, mucin function and barrier integrity have been shown to decline with age, leaving them more susceptible to bacterial penetration.

Intestinal Immune System Modulation — MAPK and TOR Pathways

Threonine is not only an important component of gastrointestinal mucin but also acts as a nutritional modulator that influences the intestinal immune system via complex signaling networks, particularly the MAPK and TOR signaling pathways. These pathways regulate the expression of immune-related genes, the production of inflammatory cytokines, and the proliferation and differentiation of immune cells in the gut-associated lymphoid tissue.

Immunoglobulin Synthesis and Immune Regulation

Threonine is involved in the synthesis of immunoglobulins, which play a critical role in immune regulation and host defense. Studies have demonstrated that increased levels of standardized ileal digestible threonine attenuate intestinal damage and immune responses in Escherichia coli-challenged weaned piglets, and that dietary threonine supplementation improves the immune status of animals under sanitary challenge.

Attenuation of Intestinal Inflammation

Threonine attenuates lipopolysaccharide-induced intestinal inflammatory responses. It also has to improve intestinal morphology and adjust the synthesis of mucin and immunoglobulins. These effects are mediated through the modulation of inflammatory signaling pathways and the support of mucosal barrier integrity.

The Bioavailability Challenge

Despite its essential physiological functions, native L-threonine presents significant absorption challenges. As a large neutral amino acid, it competes with other LNAAs for transport across the intestinal epithelium via the L-type amino acid transporter (LAT1). This competition limits the fraction of orally administered L-threonine that reaches systemic circulation and target tissues. Intestinal inflammation is known to increase gastrointestinal threonine uptake and mucin synthesis, indicating that the demand for threonine can exceed supply under conditions of gut stress.

liposomal encapsulation addresses these limitations through a phospholipid bilayer that protects L-threonine during digestive transit and provides an alternative absorption pathway that bypasses the competitive LNAA transporter. Liposomal delivery systems encapsulate amino acids in phospholipid-based liposomes, which enhance absorption and bioavailability, protect sensitive ingredients from oxidative degradation, and provide a gradual, sustained release for prolonged efficacy.

Liposomal L-Threonine

Liposomal encapsulation of L-threonine provides a fundamentally different delivery mechanism from conventional forms. The phospholipid bilayer surrounds the L-threonine molecule, forming a protective shell that enhances stability, absorption, and cellular uptake. This delivery system:

• Enhances absorption and bioavailability compared to conventional forms

• Protects L-threonine from premature metabolism in the gastrointestinal tract

• Bypasses the competitive LNAA transport pathway

• Provides targeted delivery to intestinal tissues for mucin synthesis support

• Offers sustained release for prolonged efficacy

Lipoamino acids are encapsulated in liposomes, allowing for superior bioavailability compared to standard amino acids, ensuring more of the active nutrient reaches the bloodstream and cells. The phospholipid bilayer protects the amino acid from degradation and provides a gradual, sustained release, making liposomal L-threonine an ideal ingredient for high-efficiency gut health and immune support supplements.

Clinical Evidence

Safety and Tolerability — Randomized Controlled Trial

A randomized double-blind controlled trial evaluated the safe utilization of L-threonine for supplementation in healthy adults. The study administered graded doses of L-threonine to healthy adult males and established a no-observed-adverse-effect level (NOAEL) of 12 g/day. These results support the safety of L-threonine supplementation at doses well above typical dietary intake.

Regulatory Safety Assessment

The Norwegian Scientific Committee for Food Safety (VKM) concluded that specified doses of 1,000, 1,200, 1,500, 2,000, and 2,400 mg/day of L-threonine in food supplements are unlikely to cause adverse health effects in children aged 10 to <14 years, adolescents aged 14 to <18 years, and adults aged ≥18 years. This assessment was based on four human studies (two two-week studies, one eight-week study, and a small one-year pilot study) and one four-week animal toxicity study.

Intestinal Barrier and Immune Function — Preclinical and Mechanistic Evidence

Multiple studies have demonstrated the functional role of threonine in intestinal barrier function and immune modulation. Increased levels of standardized ileal digestible threonine attenuate intestinal damage and immune responses in Escherichia coli-challenged weaned piglets. Threonine is important for mucin and immunoglobulin production, and dietary threonine supplementation has been shown to improve intestinal morphology and immune status under sanitary challenge.

Safety and Regulatory

L-Threonine is generally well tolerated at commonly used doses. A randomized double-blind controlled trial established a no-observed-adverse-effect level (NOAEL) of 12 g/day in healthy adult males. Doses of up to 4 grams daily have been used safely for up to 12 months. The VKM concluded that specified doses of 1,000–2,400 mg/day of L-threonine in food supplements are unlikely to cause adverse health effects in children, adolescents, and adults.

Regulatory status varies by region:

• United States — L-Threonine is regulated as a dietary supplement ingredient and is Generally Recognized As Safe (GRAS) for use in food and dietary supplements.

• European Union — L-Threonine is authorized for use in food supplements in EU member states, with regulatory status varying by country.

• Global Standards — L-Threonine is monographed in the USP, European Pharmacopoeia, and Japanese Pharmacopoeia (JP) with an assay specification of 98.5%–101.5% on dried basis.

Testing protocols must adhere to international standards including USP, European Pharmacopoeia, and FAO/WHO Codex Alimentarius. Formulators should verify local regulatory requirements prior to market entry.

This product is intended for research, nutraceutical, and functional food applications. Not intended to diagnose, treat, cure, or prevent any disease.

78$/KG